
CLAIMS


1. An antibody-drug conjugate represented by formula (II) to formula (IV):



(I)


or

;




(II)

or



(III)

or



(IV)

wherein,

A is an antibody or a functional binding fragment thereof;

B_1, B_2, B_3, ..., and B_n are cysteine or a derivative thereof, which may be the same or different; B_1 and B_2, B_2 and B_3, ..., B_{n-1} and B_n are linked via a peptide bond through a dehydration condensation reaction;

L_1, L_2, L_3, L_4, ..., and L_{n+1} are each independently a linker, which may be the same or different; L_1 is covalently linked to the amino terminus of B_1, L_2 and B_1, L_3 and B_2, L_4 and B_3, ..., L_{n+1} and B_n are covalently linked via a thiol group, and L_2 and D_1, L_3 and D_2, L_4 and D_3, ..., L_{n+1} and D_n are covalently linked;

D_1, D_2, D_3, ..., and D_n are each independently an active drug, ~~which may be~~and


the drug is the same ~~or different~~;

Z is ~~a group~~ covalently linked to the carbonyl group of B_1 in formula (I), the carbonyl group of B_2 in formula (II), the carbonyl group of B_3 in formula (III) or the carbonyl group of B_n in formula (IV) ;

n is an integer greater than or equal to 4, which represents the number of branches linking to the active drugs; and

m is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7 and 8~~.~~;

the structures of B_1, B_2, B_3, ..., and B_n are respectively represented by formula (V):




(V)

,

wherein p is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7 and 8; and

~~2. The antibody-drug conjugate according to claim 1, wherein the structures of B_1, B_2, B_3, ..., and B_n are respectively represented by formula (V):~~




(V)


~~;~~

~~wherein p is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7 and 8.~~


~~3. The antibody-drug conjugate according to claim 1, wherein~~ Z is selected from the group consisting of:


OH, **SH**, **NH_2**, 


42. The antibody-drug conjugate according to ~~any one of the preceding~~ claim~~s~~ 1, which has a structure represented by formula (VI-1) to (VI-5):





(VI-1)













(VI-2)




(VI-3)



(VI-4)

and



wherein

A is an antibody or a functional binding fragment thereof;

L_1, L_2, L_3, L_4 and L_5 are each independently a linker, which may be the same or different;

D_1, D_2, D_3 and D_4 are each independently an active drug, which may be the same or different; and

m is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7 and 8.

~~5~~3. The antibody-drug conjugate according to ~~any one of the preceding~~ claims 1 or 2, wherein L_1 is covalently linked to an amino residue or a thiol residue of the antibody; preferably, L_1 is covalently linked to a thiol group of the antibody; more preferably, L_1 is covalently linked to a thiol residue formed by breaking an interchain disulfide bond of the antibody.


~~6~~4. The antibody-drug conjugate according to any one of the preceding claims, wherein each of L_1, L_2, L_3, L_4, ..., and L_{n+1} ~~are~~ is independently selected from a cleavable linker, ~~a combination of cleavable linkers or~~and a non-cleavable linker.


~~7~~5. The antibody-drug conjugate according to claim ~~6~~4, wherein the cleavable linker ~~includes~~ is a peptide linker ~~and~~ or a polysulfide bond, and wherein


the peptide linker comprises 2 to 20 amino acids, preferably the peptide linker is selected from the group consisting of -valine-citrulline- (-Val-Cit-), -glycine-glycine-phenylalanine-glycine- (-Gly-Gly-Phe-Gly-), -valine-alanine- (-Val-Ala-), -valine-lysine- (-Val-Lys-), -valine-arginine- (-Val-Arg-), -phenylalanine-citrulline- (-Phe-Cit-), -phenylalanine-lysine- (-Phe-Lys-), -phenylalanine-arginine- (-Phe-Arg-) and a combination thereof; and

the polysulfide bond contains 2 to 8 sulfur atoms, preferably the polysulfide bond is selected from the group consisting of a disulfide bond (-S-S-), a trisulfide bond (-S-S-S-) and a tetrasulfide bond (-S-S-S-S-).



~~8~~6. The antibody-drug conjugate according to any of the preceding claims, wherein L_1 includes the following structures:




,



,

,



,

,



,




,

,















,

,


,

,


,

,


,

,









,

,


,

,

,

,

,

,

,

,

,

,

,

,

,





,















,




,


,

,

,

,

,

and

.

97. The antibody-drug conjugate according to any one of the preceding claims, wherein L_2, L_3, L_4, ..., and L_{n+1} includes the following structures:


,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

and .

~~10~~8. The antibody-drug conjugate according to any one of the preceding claims, wherein the antibody or functional binding fragment thereof includes a monoclonal antibody, a polyclonal antibody, an antibody fragment, Fab, Fab', Fab'-SH, $F(ab')_2$, Fv, single chain Fv ("scFv"), a diabody, a linear antibody, a bispecific antibody, a multispecific antibody, a chimeric antibody, a humanized antibody, a fully human antibody, or a fusion protein containing an antigen-binding fragment of antibody; preferably, the antibody is a humanized monoclonal antibody or a fully human antibody.

~~11~~9. The antibody-drug conjugate according to claim ~~10~~8, wherein the antibody is an IgG antibody or a functional binding fragment thereof, preferably, the antibody is selected from the group consisting of IgG_1, IgG_2, IgG_3 and IgG_4 antibodies.

~~12~~10. The antibody-drug conjugate according to any one of the preceding claims, wherein the active drug is selected from the group consisting of a cytotoxic molecule, a cell differentiation factor, a stem cell trophic factor, a steroids drug, a drug for treating an autoimmune disease, an anti-inflammatory drug and a drug for treating an infectious disease.


~~13~~11. The antibody-drug conjugate according to claim ~~12~~10, wherein the cytotoxic molecule includes a tubulin inhibitor and a DNA damaging agent;


preferably, the tubulin inhibitor includes a cytotoxic molecule of dolastatins and auristatins, a cytotoxic molecule of maytansines; the DNA damaging agent includes calicheamicins, duocarmycins, pyrrolobenzodiazepine (PBD) ~~a derivative of~~


~~anthramycin~~, camptothecins ~~and derivatives thereof~~, and SN-38;


more preferably, the ~~cytokine~~ cytotoxic molecule of auristatins includes MMAE~~,~~ and MMAF~~, and a derivative thereof~~; and the cytotoxic molecule of maytansines includes DM1~~,~~ and DM4~~, and a derivative thereof~~; and


more preferably, the cytotoxic molecule includes the following structures:



,



,



,



,



,



,



,












,


,



,


,



,


,

,

,

,

,

,

,

,

, and

.


~~14~~12. The antibody-drug conjugate according to any one of the preceding claims, which has a structure represented as follows:




ADC-1




ADC-2




ADC-3




ADC-4




ADC-5




ADC-6




ADC-7




ADC-8




ADC-9




ADC-10




ADC-11




ADC-12




ADC-13




ADC-14




ADC-15




ADC-16




ADC-17




ADC-18




ADC-19




ADC-20




ADC-21




ADC-22




ADC-23




ADC-24




ADC-25




ADC-26




ADC-27




ADC-28




ADC-29




ADC-30




ADC-31



ADC-32



ADC-33 and



ADC-34

wherein

A is an antibody or a functional binding fragment thereof; and

m is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7 and 8.

~~15~~13. A pharmaceutical composition comprising an effective amount of the antibody-drug conjugate according to any one of claims 1 to ~~14~~12, or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable excipient.

~~16. Use of the antibody-drug conjugate according to any one of claims 1 to 14 for the manufacture of a medicament for the treatment of cancer.~~